Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5849398 | 0.81 | NPC1 (0.49) | ALDH1A1KDM4ENPC1SMN1; SMN2MAPT | |
| SCHEMBL1164374 | 0.79 | SMN1; SMN2 (0.55) | ALDH1A1KDM4ENPC1SMN1; SMN2MAPT | |
| SCHEMBL1003749 | 0.79 | CYP19A1 (0.58) | ALDH1A1KDM4ENPC1SMN1; SMN2MAPT | |
| SCHEMBL2439328 | 0.78 | NPC1 (0.52) | ALDH1A1KDM4ENPC1SMN1; SMN2MAPT | |
| SCHEMBL6646535 | 0.76 | AURKA (0.48) | ALDH1A1KDM4ENPC1SMN1; SMN2MAPT | |
| SCHEMBL27754726 | 0.76 | HSP90AA1 (0.42) | KDM4EMEN1KMT2A | |
| SCHEMBL27110794 | 0.75 | KDM4E (0.50) | ALDH1A1KDM4ENPC1SMN1; SMN2MAPT | |
| SCHEMBL28019782 | 0.75 | NPC1 (0.48) | ALDH1A1KDM4ENPC1SMN1; SMN2MAPT | |
| SCHEMBL16815851 | 0.75 | SMN1; SMN2 (0.48) | ALDH1A1KDM4ENPC1SMN1; SMN2MAPT | |
| SCHEMBL1921676 | 0.74 | NOS2 (0.44) | KDM4ETDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023242228-A1 | 4-SUBSTITUTED (1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLES AS BUB1 INHIBITORS USEFUL FOR TREATING CANCERS | UNIVERSITEIT LEIDEN (NL) | 2023-12-21 | — | — | WO | disclosed |
| CN-103976958-B | Application of gold nanoparticles in preparing anticoagulants or antiplatelet drugs | 国家纳米科学中心 | 2017-03-22 | — | — | CN | disclosed |
| US-9422271-B2 | Pyrimidine compounds as tuberculosis inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-23 | — | — | US | disclosed |
| US-20140249137-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| CN-103976958-A | Application of gold nanoparticles in preparing anticoagulants or antiplatelet drugs | NAT CT NANOSCIENCE NCNST CHINA | 2014-08-13 | — | — | CN | disclosed |
| CN-102188383-B | Amiopyrimidine-modified gold nano particles and preparation method and use thereof | NAT CT NANOSCIENCE NCNST CHINA | 2014-05-07 | — | — | CN | disclosed |
| CN-102188383-A | Amiopyrimidine-modified gold nano particles and preparation method and use thereof | NAT CT NANOSCIENCE NCNST CHINA | 2011-09-21 | — | — | CN | disclosed |
| WO-2011106993-A1 | GOLD NANOPARTICLES MODIFIED BY AMINOPYRIMIDE, PREPARATION METHOD AND USE THEREOF | 国家纳米科学中心 (CN) | 2011-09-09 | — | — | WO | disclosed |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-03 | — | — | US | disclosed |
| EP-1888565-A2 | 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006110884-A2 | 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249137-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | TYMS, TYMP, DPYD | ALDH1A1 1449/4885KDM4E 2345/4885NPC1 1434/4885 |
| US-20110053916-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | TYMS, TYMP, DPYD | ALDH1A1 1449/4885KDM4E 2345/4885NPC1 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.